Gemma N. Jones
AstraZeneca (Singapore)(SG)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, CRISPR and Genetic Engineering, Cell death mechanisms and regulation, Connective tissue disorders research
Most-Cited Works
- → RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer(2018)417 cited
- → The in vitro pharmacology of ZM 241385, a potent, non‐xanthine, A2aselective adenosine receptor antagonist(1995)363 cited
- → The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models(2018)302 cited
- → Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial(2021)204 cited
- → Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells(2020)182 cited
- → Pharmacology of the ATM Inhibitor AZD0156: Potentiation of Irradiation and Olaparib Responses Preclinically(2019)157 cited
- → Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues(2010)154 cited
- → Valproic Acid Confers Functional Pluripotency to Human Amniotic Fluid Stem Cells in a Transgene-free Approach(2012)152 cited
- → Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study(2021)126 cited
- → Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance(2022)82 cited